AAV-mediated systemic delivery of human IFN-β (AAV-hIFN-β) in combination with low-dose cyclophosphamide showed anti-angiogenic activity with down regulation of VEGF and FGF-2 and also caused complete tumor regression in orthotopic retroperitoneal and disseminated models of neuroblastoma [95]. This evidence concerns the gene VEGFA and neoplasm.